James E. Flynn’s Deerfield Management Reveals Passive Stake in Amphastar Pharmaceuticals Inc. (AMPH)

James E. Flynn, the manager of Deerfield Management, has disclosed a new passive stake in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH). Mr. Flynn owns 1.83 million shares of the company, equivalent to 4.22% of common stock, a new filing with the U.S. Securities and Exchange Commission showed.

Amphastar logo

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is a specialty pharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable and inhalation products. Recently, the company conducted a public offering in which it issued 8.0 million shares of its common stock, including 3.36 million shares from the selling stockholders. The offering was priced at $7.00 per share for a total offering amount of $56 million, according to a press release.

The underwriters were granted a 30-day option to purchase up to an additional 1.20 million shares of common stock. The underwriters exercised in full their option to purchase from the company all these additional shares of common stock at the initial public offering price of $7.00 per share. Including the exercise of the over-allotment option, the company has sold a total of 5.84 million shares of its common stock.

Deerfield Management is a healthcare focused investment firm specializing in funding R&D, managing hostile takeovers, corporate transitions and financial advisory services. The fund oversees $3.5 billion in assets. At the end of April, Deerfield reported a new stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP), owning nearly 660,000 shares. In addition, the fund revealed raising its position in Trivascular Technologies Inc (NASDAQ:TRIV), holding around 1.70 million shares from 632,700 shares.

Also, in the month of April, Deerfield increased its stake in Insmed Incorporated (NASDAQ:INSM) to 3.04 million shares, equal to 7.75% of the company’s common shares.

Disclosure: none

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click Here to Read Comments
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!